We read with interest the comments by Dr Piccaluga et al 1, 2 regarding our report on the use of alemtuzumab in an adult patient with refractory acute lymphocytic leukemia (ALL), who has now remained in complete remission for 20 months and remains so at the time of writing, albeit still without complete recovery of normal blood counts, as initially reported. 3 We have extended our experience on three additional patients with refractory ALL. In the first one, we observed no response; we checked for the presence of the CD52 antigen at the surface of blast cells and found that it was absent and not covered by the CD52 antibody administered, using a human anti-IGG globulin. A second patient had a CD52-positive refractory ALL3 with very high tumor load: we observed a reduction in testicular leukemic infiltration and a weak and transient decrease in peripheral blood blast cell counts, but the marrow aspirate remained infiltrated. The third patient had a hypercellular Ph1-positive ALL diagnosed in December 2003. He was treated by hyper C-VAD and imatinib. He reached complete cytological and chromosomal remission in March 2004, but within 6 weeks, Ph1-positive cells had reappeared and the molecular quantification of the b2a3 transcript was very high. Mab Campath was introduced and imatinib pursued. After six infusions of alemtuzumab, in May 2004, we observed a disappearance of Ph1-positive cells in the marrow and a profound decrease in b2a3 quantification. Unfortunately, we discontinued Mab Campath because of severe neurologic toxicity (peripheral neuropathy and myelitis) of unknown origin since we could not rule out its responsibility. It should be mentioned that in July 2004, Avivi et al 4 reported for the first time similar neurological complications following alemtuzumab-based reduced intensity allogeneic transplantation.
TO THE EDITOR
We read with interest the comments by Dr Piccaluga et al 1, 2 regarding our report on the use of alemtuzumab in an adult patient with refractory acute lymphocytic leukemia (ALL), who has now remained in complete remission for 20 months and remains so at the time of writing, albeit still without complete recovery of normal blood counts, as initially reported. 3 We have extended our experience on three additional patients with refractory ALL. In the first one, we observed no response; we checked for the presence of the CD52 antigen at the surface of blast cells and found that it was absent and not covered by the CD52 antibody administered, using a human anti-IGG globulin. A second patient had a CD52-positive refractory ALL3 with very high tumor load: we observed a reduction in testicular leukemic infiltration and a weak and transient decrease in peripheral blood blast cell counts, but the marrow aspirate remained infiltrated. We share the remarks of P Piccaluga et al: Mab Campath, as shown with other monoclonal antibodies, should be used on low tumor load, and probably maintenance therapy is needed.
Although the data are scanty, we now reserve its use to ALL bearing the CD52 epitope and the CD52 antibody has been added to our immunophenotyping panel in order to select for the adequate patients. As indicated in our publication, we believe that the addition of cytokines, G-CSF in particular, may add to its efficacy by boosting ADCC.
In the absence of major other development for the treatment of adult ALL, which remains deceiving even with allogeneic stem cell transplantation, 5 we agree with the Bologna team that alemtuzumab at present time may be one of the best options to investigate along the lines described here and post transplantation.
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